Fluoroquinolones are widely used in the management of infectious diseases, and are generally safe and well tolerated. However, immediate hypersensitivity reactions, including anaphylactic reactions, have been reported. We present here a case of anaphylactic shock in a 26-year-old man following intravenous levofloxacin administration. Skin tests confirmed an immediate hypersensitivity reaction to levofloxacin. Subsequent oral challenge tests for garenoxacin, which showed negative skin test results, confirmed that garenoxacin was well tolerated. This is the first report of tolerance to full-dose garenoxacin in a patient who developed an immediate hypersensitivity reaction to levofloxacin.
Introduction
Fluoroquinolones are important therapeutic agents in the management of infectious diseases. They are generally safe and well tolerated, but immediate hypersensitivity reactions, such as anaphylactic reactions, have been documented for various fluoroquinolones (1) . An anaphylactic reaction to levofloxacin is estimated to occur in one per million patients treated (2) .
We describe here a patient who developed anaphylactic shock following intravenous levofloxacin administration, in whom subsequent skin tests confirmed an immediate hypersensitivity reaction to levofloxacin. We also investigated the cross-reactivity with other fluoroquinolones, and confirmed the patient's tolerance to garenoxacin by oral challenge tests.
Case Report
A 26-year-old man with a 2-week history of dry cough, fever and general fatigue was admitted to our hospital for refractory pneumonia. He had been previously treated at another hospital with piperacillin and azithromycin 4 days before admission, with no clinical improvement. There was no history of previous illness including allergic diseases or any drug allergies. He had not been prescribed levofloxacin in the past.
On admission, the patient was alert and physical examination revealed elevated body temperature (38.7 ), regular pulse (84 beats/min), normal blood pressure (101/74 mm Hg), and normal oxygen saturation (97%) on room air. Auscultation of the chest revealed no abnormalities, with regular heart sounds and no murmurs. No palpable lymphadenopathy was noted.
Laboratory test results were as follows: white blood cell count, 11,100/mm 3 (88.9% neutrophils); C-reactive protein, 1.3 mg/dL (<0.5 mg/dL); aspartate aminotransferase, 96 U/L (<38 U/L); alanine aminotransferase, 49 U/L (<36 U/L); alkaline phosphatase, 199 U/L (<359 U/L); total bilirubin, 1.0 mg/dL (<1.3 mg/dL); lactate dehydrogenase, 177 U/L (<237 U/L); creatinine, 0.8 mg/dL (<1.2 mg/dL); serum sodium, Tests for serum IgM antibodies against Mycoplasma pneumoniae were strongly positive (160-fold), as determined by the particle agglutination method. The finding for cold agglutines was also positive, with a titer of 1:256. A chest radiograph showed infiltrate in the lower field of the right lung, while chest computed tomography (CT) showed consolidation in the right middle lobe. The patient was diagnosed with M. pneumoniae infection and he was started on intravenous levofloxacin therapy (500 mg once a day).
Soon after starting intravenous levofloxacin, the patient developed chest tightness, dyspnea, wheezing, and impaired consciousness. Systolic blood pressure decreased to 60 mmHg and oxygen saturation decreased to 70%; the patient was therefore placed on a non-rebreather mask with 100% fraction of inspired O2. Levofloxacin infusion was terminated as soon as signs of hypersensitivity were observed, and epinephrine 0.3 mg was administered immediately along with d-chlorpheniramine 4 mg and methylprednisolone 500 mg, all given intravenously. Dopamine was required for 2 days to maintain blood pressure within normal limits. Thereafter, his condition improved. The patient fully recovered from the hypersensitivity reaction with no apparent complications.
After obtaining informed consent from the patient, we performed skin prick tests with levofloxacin, ofloxacin (the levogyre form of levofloxacin), piperacillin, and azithromycin, with negative results (Table 1) . Normal saline was used as a negative control. Skin scratch tests with levofloxacin and ofloxacin were positive, but were negative with piperacillin and azithromycin ( Fig. 1 and Table 1 ). As positive results were obtained with levofloxacin in the skin scratch tests, we did not perform intradermal tests. Rechallenge tests with piperacillin and azithromycin at therapeutic doses confirmed their safety; therefore, we confirmed the causative agent of the patient's anaphylactic reaction to be levofloxacin.
To investigate whether other available fluoroquinolones were safely tolerated by the patient, we performed skin prick tests and scratch tests with other fluoroquinolones. The skin prick tests all showed negative results, but the skin scratch tests showed varying results for the fluoroquinolones tested ( Fig. 2 and Table 2 ). Pazufloxacin was strongly positive, inducing erythema and wheal formation. Ciprofloxacin (tablet,
Discussion
Levofloxacin, which is a potent and broad-spectrum antibiotic, is one of the most widely used fluoroquinolones. The intravenous formulation of levofloxacin was introduced in Japan in December 2010. Levofloxacin can be given orally or intravenously at a daily dose of 500 mg once daily. This dosage has been approved for use in the ambulatory treatment of community-acquired pneumonia and while generally safe, the literature contains some reports of hypersensitivity reactions, including anaphylactic reactions, to levofloxacin (3) (4) (5) .
Because anaphylactic reactions are potentially life threatening, it is important to determine which drug is the cause of any reaction. As it has been reported that fluoroquinolones rarely test positive on skin tests (6), skin tests are generally not carried out before administering fluoroquinolones. In the present patient, we carried out a skin test after the patient developed anaphylactic shock following intravenous levofloxacin administration, and levofloxacin showed an immediate hypersensitivity reaction in skin tests. Thus, in cases where the patient has received multiple drugs and the causal drug is unclear, skin tests can be effective diagnostically.
Cross-reactivity studies between fluoroquinolones have concluded that the level of cross-reactivity among this group of antibiotics is significant, and all fluoroquinolones should be avoided in a patient intolerant to a specific fluoroquinolone (7). However, low cross-reactivity between levofloxacin and other fluoroquinolones has also been suggested (6) . Therefore, in the present patient, we considered it useful to determine whether alternative fluoroquinolones could be used safely in an infection in the future. All fluoroquinolones consist of a bicyclic ring structure. Levofloxacin, ofloxacin, and pazufloxacin all have a common unique ring structure added to the bicyclic ring structure. The present patient showed immediate hypersensitivity reactions to levofloxacin, ofloxacin, and pazufloxacin, but not to garenoxacin or moxifloxacin. Ciprofloxacin showed different results depending on the concentration, and erythema appearing in the positive skin scratch test was faint. We speculate that the positive result was not due to allergy but to scratch stimulation. It is plausible therefore that, the crossreactivity seen in the present patient was related to the unique ring structure. Hence, we chose garenoxacin, which has the standard bicyclic ring structure and for which the patient tested negative in the skin tests, for the oral challenge tests. These oral challenge tests with garenoxacin were carefully performed and its tolerance was confirmed.
To the best of our knowledge, this is the first report of tolerance to full-dose garenoxacin in a patient who developed an immediate hypersensitivity reaction to levofloxacin. According to the skin tests and oral challenge test results, we think garenoxacin can be used safely in the future treatment of this patient. However, the mechanisms of crossreactivity among fluoroquinolones are not yet fully understood, and the possibility of acquiring cross-reactivity to garenoxacin in the future cannot be ruled out. Therefore, garenoxacin should be used only when the benefits outweigh the risks for future treatment requiring a fluoroquinolone antibiotic.
In summary, we reported here a case of anaphylactic shock induced by levofloxacin. Clinicians should be cognizant of this rare, potentially fatal adverse drug reaction. Further, because of the low cross-reactivity rate between levofloxacin and other fluoroquinolones, it is important to carry out challenge tests for other fluoroquinolones to confirm the patient's sensitivity or reactivity.
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